Publications by authors named "J Moslehi"
Article Synopsis
- AZD5991 is a drug being tested for safety and effectiveness in patients with relapsed or refractory blood cancers, both by itself and alongside another drug called venetoclax.
- The clinical trial involved 61 patients receiving varying doses of AZD5991, while 17 patients took it in combination with venetoclax, focusing on determining safe dosage levels and any anti-cancer effects.
- Results showed significant side effects such as diarrhea and nausea, with a low overall response rate to treatment, despite a few patients achieving partial or complete remission.
In the past 20 years, cardio-oncology has emerged as a new cardiovascular subspeciality. Older, non-specific chemotherapies (such as anthracyclines) and radiation had been well-described cardiotoxic agents, with anthracycline-associated heart failure initially extensively studied in the pediatric population by Drs. Steven Lipshultz (a cardiologist) and Stephen Sallan (an oncologist).
View Article and Find Full Text PDFArticle Synopsis
- Immunological therapies, including immune checkpoint inhibitors (ICIs) and cell-based therapies like CAR-T, have transformed cancer treatment by enabling the immune system to target cancer cells.
- While these therapies are generally effective, they can cause immune-related adverse events (irAEs) that vary in severity and timing, from mild skin rashes to serious complications such as myocarditis or cytokine release syndrome.
- The statement discusses the growing understanding of cardiovascular toxicities associated with these therapies, outlines their diagnosis and management, and identifies gaps in current research that need further exploration.
Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all patients with cancer eligible for treatment with ICIs. However, patients on ICI therapy are at risk for immune-related toxicities that can affect any organ. Inflammation of the heart muscle, known as myocarditis, resulting from ICI targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) is an infrequent but potentially fatal complication.
View Article and Find Full Text PDF